Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines (Q37129949)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18765555%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

title

Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18765555%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

0 references

1 reference

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18765555%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

13

Steven A Rosenberg

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18765555%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

7

Udai S Kammula

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18765555%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

8

Marybeth S Hughes

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18765555%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

12

Seth M Steinberg

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18765555%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

2

Stephanie G Downey

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18765555%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

3

Jacob A Klapper

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18765555%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

author name string

Franz O Smith

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18765555%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

James C Yang

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18765555%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

Richard M Sherry

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18765555%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

Richard E Royal

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18765555%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

Catherine L Levy

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18765555%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

Donald E White

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18765555%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

language of work or name

English

0 references

publication date

1 September 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18765555%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

published in

Clinical Cancer Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18765555%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18765555%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

issue

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18765555%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

page(s)

5610-5618

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18765555%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

cites work

Cancer statistics, 2007

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2656367

Cancer immunotherapy: moving beyond current vaccines

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2656367

An evidence-based staging system for cutaneous melanoma

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2656367

Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2656367

Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2656367

Interleukin-2: clinical applications

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2656367

Guidelines for the safe administration of high-dose interleukin-2.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2656367

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2656367

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2656367

Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2656367

Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2656367

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2656367

High-Dose Regimen of Interleukin-2 and Interferon-Alpha in Combination with Lymphokine-Activated Killer Cells in Patients with Metastatic Renal Cell Cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2656367

Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2656367

Reporting results of cancer treatment

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2656367

Effects of route and formulation on clinical pharmacokinetics of interleukin-2.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2656367

Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2656367

Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2656367

Low-Dose Intravenous Bolus Interleukin-2 with Interferon-Alpha Therapy for Metastatic Melanoma and Renal Cell Carcinoma

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2656367

Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study

3 September 2018

1 reference

12 December 2020

Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2

1 reference

12 December 2020

Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone

1 reference

12 December 2020

Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues

1 reference

12 December 2020

Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides

1 reference

12 December 2020

Daily low-dose subcutaneous recombinant interleukin-2 by alternate weekly administration: antitumor activity and immunomodulatory effects

1 reference

12 December 2020

Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response

1 reference

12 December 2020

10.1158/1078-0432.CCR-08-0116

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18765555%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18765555%20AND%20SRC:MED&resulttype=core&format=json

13 January 2020

PubMed publication ID

18765555

1 reference